Contraceptive Market by Product (Devices, Drugs), Gender (Female Contraceptive, Male Contraceptive), Method, Distribution - Global Forecast 2024-2030

[187 Pages Report] The Contraceptive Market size was estimated at USD 48.43 billion in 2023 and expected to reach USD 54.87 billion in 2024, at a CAGR 13.82% to reach USD 119.89 billion by 2030.

Contraceptives, also known as birth control, are methods or devices used to prevent pregnancy. These products or practices can work in various ways, such as inhibiting the fertilization of an egg, preventing the implantation of a fertilized egg in the uterus, or regulating hormonal cycles. The availability and choice of contraception provide individuals with the ability to plan if and when they want to have children, contributing to better health outcomes for women and families. Increased educational campaigns and government initiatives to raise awareness about sexual health and contraceptives have increased the adoption of various contraceptive methods. Further, enhanced access to healthcare services and family planning in emerging economies has increased the use of contraceptives. Innovations in contraceptive methods leading to more efficient and user-friendly options also bolstered the market growth. However, strict regulatory frameworks can delay product approvals and launches. Resistance in certain regions due to traditional beliefs and religious constraints may pose challenges for the market. Nevertheless, investigating biodegradable and eco-friendly contraceptive products to cater to environmentally conscious consumers is expected to provide an opportunistic way for market growth. Moreover, developments in male contraception methods may bolster the market growth shortly.

Condoms are a widely used barrier method of contraception that provides both birth control and protection against sexually transmitted infections (STIs). Condoms are usually made of latex, polyurethane, or lambskin and are designed to be used once and disposed of after use. The diaphragm is a shallow, dome-shaped cup made of silicone or latex that is inserted into the vaginal cavity to cover the cervix and block sperm from reaching the ovum. Diaphragms are available in various sizes, and a healthcare provider must fit them to ensure proper use and maximum protection. Intrauterine devices (IUDs) such as Copper IUDs release a small amount of copper into the uterus, which creates a toxic environment for sperm. Hormonal IUDs release progestin, a hormone that thickens the cervical mucus to prevent sperm flow from reaching the egg and sometimes suppresses ovulation. Subdermal implants are small, rod-shaped devices inserted below the upper arm, releasing a continuous amount of progestin hormone to prevent ovulation. Vaginal rings, such as the NuvaRing, are flexible plastic rings that are inserted into the vagina and release both estrogen and progestin to offer month-long pregnancy protection. Injectable contraceptives are injections of progestin given by a healthcare professional every three months as an alternative to daily contraceptive pills. Oral contraceptive pills (OCPs) are the most common methods of contraception, available in various formulations of estrogen and progestin for optimal effectiveness. The transdermal patch is a hormonal contraceptive applied to the skin, releasing progestin and estrogen into the bloodstream to effectively control contraception.

The female contraceptive comprises a diverse range of products aimed at enabling women to prevent unintended pregnancies. These methods include hormonal contraceptives such as oral contraceptive pills, injectables, and patches, as well as intrauterine devices (IUDs), both hormonal and copper-based. Contraceptive methods, including diaphragms, cervical caps, and female condoms, also contribute to the options available, alongside emergency contraceptive pills and permanent solutions such as tubal ligation. The most common male contraceptives include condoms and vasectomy, a permanent surgical procedure. However, there are promising developments in the field of male contraception, such as hormonal gels and injections that aim to inhibit sperm production temporarily. Furthermore, research into non-hormonal methods, including the reversible inhibition of sperm under guidance (RISUG) and a similar method in the U.S. known as Vasalgel, which acts as a physical barrier inside the vas deferens, is expanding. The acceptance and popularity of male contraceptives are influenced by cultural attitudes, perceived responsibility in family planning, and the convenience of use.

Barrier methods of contraception work by preventing the sperm from reaching the egg. These include male and female condoms, diaphragms, cervical caps, and contraceptive sponges, providing a physical or chemical barrier during sexual activities. Male condoms are the most widely used barrier method as they are readily available and easy to use. In addition to preventing pregnancy, these are effective in reducing the risk of various sexually transmitted infections (STIs). Barrier methods are often favored for their lack of systemic effects on the user's hormones. Hormonal contraceptives contain synthetic hormones that mimic estrogen and progesterone's natural hormones to prevent ovulation, thicken cervical mucus, or alter the uterine lining to prevent pregnancy. These types come in various forms, including oral pills, patches, injections, vaginal rings, and intrauterine devices (IUDs). The effectiveness of hormonal methods depends on strict adherence to their usage regimen. Additionally, these methods can offer benefits such as regulated menstrual cycles, reduced menstrual cramps, and a decreased risk of certain reproductive cancers. Sterilization is a permanent form of birth control achieved through medical procedures that close or block the fallopian tubes in females (tubal ligation) or the vas deferens in males (vasectomy). The procedures are highly effective with a very low rate of failure and are best suited for individuals who are sure they do not want children in the future. Female sterilization is usually more complex and carries greater risks than male sterilization, which is often a simpler outpatient procedure. Both procedures are irreversible in most cases, and individuals considering sterilization should be counseled on the permanent nature of this contraceptive method. Surgical contraception refers to procedures that ultimately lead to sterilization, and while the term may overlap with sterilization methods mentioned, it emphasizes the factor of surgery. For women, this includes both traditional tubal ligation and more recent procedures, such as the laparoscopic placement of occlusive devices on the fallopian tubes. For men, vasectomy involves the cutting and sealing of the vas deferens. These permanent procedures require careful consideration and informed consent, as reversal attempts may not be successful and are often costly.

The rise of eCommerce has expanded the availability of contraceptives through online platforms. These digital marketplaces allow consumers to purchase contraceptives discretely and conveniently, providing access to various products that may not be available in their immediate geographical area. Clinics serve as a primary distribution channel for contraceptives, particularly for forms requiring prescription or medical consultation, such as birth control pills, IUDs, and injectables. These healthcare facilities provide an opportunity for individuals to receive personalized advice and guidance from health professionals about the most appropriate contraceptive method for their needs. Clinics may be affiliated with larger healthcare institutions or operate independently, often focusing on sexual and reproductive health. They often work in conjunction with public health initiatives to provide affordable or free contraceptives to underprivileged populations. On the other hand, Government networks, including Primary Health Centers, Community Health Centers, State AIDS Control Societies, and many others, distribute contraceptives often at reduced or no cost, targeting lower-income brackets and regions with limited access to healthcare. These networks have a crucial role in public health initiatives and are instrumental in making contraceptives accessible to a broader audience. Further, hospital pharmacies are integral to the distribution network for contraceptives as they provide immediate access to postpartum and post-abortion contraceptives. Hospitals with specialized reproductive health or family planning divisions may need such products more. Hospital pharmacies are an important access point for patients seeking confidentiality and direct recommendations from healthcare providers during their hospital stay. Furthermore, independent and chain pharmacies offer valuable services catering to different aspects of contraceptive access. Independents focus on personalized care and community integration, while chains excel in price competitiveness and convenience. Independent pharmacies offer specialized compounds and a range of options tailored to consumer feedback and preferences in their local community. However, chain pharmacy product range is often standardized across locations, potentially limiting options for consumers seeking specific brands or formulations. Moreover, subscription services for contraceptives, such as birth control pills, have become increasingly popular and can improve adherence by automating the refill process.

The contraceptive market in the Americas presents a mature landscape with high awareness levels and a strong presence of major pharmaceutical companies. The region is characterized by a wide range of contraceptive methods including birth control pills, IUDs, implants, and condoms. Government policies and non-profit organizations in the United States and Canada play a crucial role in providing accessible contraception, particularly to younger and lower-income populations. The Latin American market is experiencing growth, propelled by public health initiatives aimed at reducing teenage pregnancies and increasing the availability of contraceptives. The EMEA region presents a varying landscape for contraceptives. Europe has a well-established market with high contraceptive prevalence rates, backed by governmental healthcare systems that offer various contraceptive methods at low or no cost. There is a strong tendency toward long-acting reversible contraceptives (LARCs) such as IUDs. The Middle East, contrastingly, has cultural and religious factors that influence contraceptive use, with varying degrees of accessibility and societal acceptance across different countries. The African continent shows the lowest contraceptive prevalence rate and is experiencing a rise in need for family planning services, driven by international aid, and increasing government focus on women's health issues. The Asia-Pacific region showcases a diverse contraceptive market, heavily influenced by cultural, social, and regulatory factors. The presence of high-population countries coupled with government initiatives and awareness campaigns for the use of contraceptives has propelled the market growth in the region.

The FPNV Positioning Matrix is pivotal in evaluating the Contraceptive Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Contraceptive Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• Richmond Biotech Company to buy Contraceptive biz for USD 100 Million

  Aditxt has announced its intent to acquire Evofem Biosciences, a contraceptive business located in California, for a total purchase price of USD 100 million. The agreement, which has received unanimous approval from the boards of both companies, is slated for completion in the initial half of this year. Evofem Biosciences is known for its innovative product, Phexxi, a non-hormonal contraceptive gel, and the acquisition is expected to incorporate Evofem as a wholly owned subsidiary of Aditxt, further solidifying Aditxt's position in the healthcare market while broadening its product offerings. [Published On: 2024-01-03]

• UK Launches First Trial of Hormone-free Male Birth Control pill

  UK-based Quotient Sciences has initiated the initial trials for YCT-529, an innovative non-hormonal male contraceptive pill. This landmark study, involving 16 participants, is expected to redefine birth control by offering men a hormone-free option. As the goal of gender-inclusive contraceptive methods intensifies, YCT-529 signifies a progressive stride toward balancing the responsibilities of family planning. Quotient Sciences' commitment to this novel approach could not only transform the marketplace for contraceptives but also catalyze a shift in societal norms surrounding reproductive health. [Published On: 2023-12-20]

• Aditxt Acquires Phexxi Contraceptive Gel-Maker Evofem for USD 100 million

  US-based biotech firm Aditxt has announced the acquisition of Evofem Biosciences in a strategic deal valued at approximately USD 100 million. This acquisition represents a significant step for Aditxt, marking its entrance into the sexual and reproductive health sector. This move is anticipated to broaden Aditxt's product range and reinforce its position in the market by catering to the diverse needs of consumers seeking non-hormonal contraceptive methods. [Published On: 2023-12-13]

The report delves into recent significant developments in the Contraceptive Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Acme Generics Pvt. Ltd., Afaxys, Inc., Agile Therapeutics, Inc., Amneal Pharmaceuticals LLC, ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma Limited, Bayer AG, Church & Dwight Co., Inc., HLL Lifecare Limited, Insud Pharma, S.L., Johnson & Johnson Services, Inc., Lupin Limited, Mayne Pharma Group Limited, Merck & Co., Inc., Mithra Pharmaceuticals S.A., Okamoto Industries, Inc., Organon & Co., Perrigo Company plc, Pfizer Inc., Piramal Pharma Ltd., Reckitt Benckiser Group plc, RITEX GMBH, Sanofi S.A., Say It With A Condom, LLC., Syzygy Healthcare Solutions LLC, Teva Pharmaceutical Industries Ltd., TherapeuticsMD, Inc., TTK Healthcare Limited, Veru Inc., and Viatris Inc..

This research report categorizes the Contraceptive Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Devices
    • Condoms
    • Diaphragm
    • IUDs
      • Copper IUDs
      • Hormonal IUDs
    • Subdermal Implants
    • Vaginal Rings
  • Drugs
    • Injectables
    • Oral Contraceptive Pills
    • Transdermal Contraceptive Patch
• Gender
  • Female Contraceptive
  • Male Contraceptive
• Method
  • Barrier
  • Harmonal
• Distribution
  • Chain Pharmacy
  • Clinics
  • Government Network
  • Hospital Pharmacy
  • Independent Pharmacy
  • Online Platform

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

1. What is the market size and forecast of the Contraceptive Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Contraceptive Market?
3. What are the technology trends and regulatory frameworks in the Contraceptive Market?
4. What is the market share of the leading vendors in the Contraceptive Market?
5. Which modes and strategic moves are suitable for entering the Contraceptive Market?